Macedonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
mycosis fungoides/мачнина
Врската е зачувана во таблата со исечоци
Страница 1 од 38 резултати
Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
We assessed the efficacy and toxicity of a chemotherapeutic regimen in patients with stage II-IV mycosis fungoides. Eleven previously treated outpatients received etoposide and methotrexate p.o. and bleomycin i.v. every 3 weeks. There was 1 complete remission for 2 months and 7 partial remissions
Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
METHODS
The treatment of advanced mycosis fungoides is a therapeutic challenge. A variety of treatment approaches have been used. In our experience, chemotherapy has been most useful. The purpose of this study was to evaluate the effectiveness of the synergy previously demonstrated between
Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Psoralen plus ultraviolet (UV) A (PUVA) is the standard treatment for early stage mycosis fungoides (MF). When 8-methoxypsoralen (8-MOP) is used in PUVA therapy, it often produces intolerance reactions such as nausea, vomiting and headache.
OBJECTIVE
To investigate whether
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
DAB389IL-2 is a novel fusion toxin that retargets the cytotoxic A-chain of diphtheria toxin to interleukin-2 (IL-2) receptor-expressing tumors.
OBJECTIVE
The purpose of this phase I trial was to study the toxicity, maximum tolerated dose, and clinical efficacy of DAB389IL-2 in IL-2
Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Pruritus is a symptom that significantly affects the patient's quality of life in cutaneous T cell lymphoma (CTCL). The most effective treatments are those that address the condition itself; however, it is often not possible to control this symptom. Lymphoma-related pruritus normally becomes more
Interventions for mycosis fungoides
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, a malignant, chronic disease initially affecting the skin. Several therapies are available, which may induce clinical remission for a time. This is
Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.
OBJECTIVE
To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).
METHODS
Patients received quisinostat 8 mg or 12 mg
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVE
To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas.
METHODS
Between May 1997 and February 1999, 44 previously treated
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after
Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Since the approval of vorinostat for the treatment of refractory cutaneous epidermotropic T-cell lymphoma (CTCL) in 2006, very little data about this treatment have been published. The aim of this retrospective study was to assess the efficacy and safety of vorinostat in patients with CTCL treated
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.
METHODS
Between June 2002 and February 2004,
[A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
New purine analogues, fludarabine, 2-chlorodeoxyadenosine and 2-deoxycoformycin are remarkably active in generally incurable malignant lymphoproliferative disorders. The first part of the review summarises pharmacological properties, the mechanism of action, toxicity and clinical use of fludarabine.
Најкомплетната база на податоци за лековити билки поддржана од науката
- Работи на 55 јазици
- Лекови од билки поддржани од науката
- Препознавање на билки по слика
- Интерактивна GPS мапа - означете ги билките на локацијата (наскоро)
- Прочитајте научни публикации поврзани со вашето пребарување
- Пребарувајте лековити билки според нивните ефекти
- Организирајте ги вашите интереси и останете во тек со истражувањето на новостите, клиничките испитувања и патентите
Напишете симптом или болест и прочитајте за билки што можат да помогнат, напишете билка и видете болести и симптоми против кои се користи.
* Сите информации се базираат на објавени научни истражувања
